c-erbB-2 expression is predictive for lymphatic spread of clinical gastric carcinoma

Hepato-Gastroenterology

Volumn 44, Issue 13, 1997, Pages 294-298

  Orita, Hiroyuki ^a   Maehara, Yoshihiko ^a   Emi, Yasunori ^a   Kakeji, Yoshihiro ^a   Baba, Hideo ^a   Korenaga, Daisuke ^a   Sugimachi, Keizo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

c erbB 2; Gastric carcinoma; Metastasis; Survival

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; STOMACH CARCINOMA;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 0031051916     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Akiyama T, Sudo C, Ogawa H, Tyoshima K, Yamamoto T: The product of the c-erbB-2 gene: a 185-kd glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646.
2. Schechiter A, Swem DFL, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, Ullrich A, Coussens L: The gene: an erbB homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Nature 1985; 299: 976-978.
3. Slamon DJ, Clark CM, Wong SC, Levin WJ, Ullrich A, McGuire WL: Human VJ breast cancer: correlation relapse and survival with amplificaton of the HER2/neu oncogene. Science 1987; 235: 177-182.
4. Gueria M, Barrois M, Terrier MJ, Spielmann M, Riou G: Overexpression of either c-myc or c-erbB-2/neu protooncogene in human breast carcinoma: correlation with poor prognosis. Oncogene Res. 1988; 3: 21-S1.
5. Berger MS, Locher GW, Saurer S, Gullick W, Waterfield MD, Groner B, Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988; 48: 1238-1243.
6. Wright C, Angus B, Nicholson S: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989; 49: 2087-2090.
7. Jain S, Isabel Filipe M, Gullick WJ, Jacqueleine Linehan, Morris RW: c-erbB-2 proto-oncogene expression and its relationship to survival in gastric carcinoma: An imminohistochemical study on archival material. Int. J. Cancer 1991; 48: 668-671.
8. Tateishi M, Toda T, Minamisono Y, Nagasaki S: Clinicopathologic significance of c-erbB-2 protein expression in human gastric carcinoma. J. Surg. Oncol. 1992; 49: 209-212.
9. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, Miyazaki I, Endou Y, Tanaka M, Sasaki T: Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991; 51: 1034-1038.
10. Motojima K, Furui J, Kohara V, Izawa K, Kanematu T, Shiku H: erbB expression in well-differentiated aclenocarcinoma of the stomach predicts shorter survival after curative resection. Surgery 1994; 115: 349-354.
11. Bishop Y, Fienberg S, Holland P: Discrete multivariate analysis: Theory and practice. (Cambridge: MIT Press 1975; 357-361.
12. Prentice RL: Use of the logistic model in retrospective studies. Biometrics 1976; 32: 597-606.
13. Japonese Research Society for Gastric Cancer: The general rules for gastric cancer. Jpn. J. Surg. 1981; 11: 127-145.
14. Sugano H, Nakamura K, Kato Y: Pathologic studies of human gastric cancer. Acta Pathol. Jpn. 1982; 32: 329-347.
15. Hsu SM, Raine L, Fanger H: Use of Avidin-Biotin-Peroxidase complex (AB(U) in immunoperoxidase technique: a comparison between A-B-C and unlabelled antibody (PAP) procedure. J. Histochem. Cytochem 1981; 29: 577-583.
16. Chin KY, Loke SL, Ho FCS: Immunohistochemical demonstration of c-erbB-2 oncoprotein in gastric adenocarcinoma: Comparison of cryostat and paraffin wax sections and effect of fixation. J. Clin. Pathol., 1994; 47: 117-121.
17. Dixon WJ: BMDP Statistical Software. Berkeley: University of California Press 1985: 143-594.
18. Yusa K, Sugimoto Y, Yamori T, Yamamoto T, Toyoshima K, Tsuruo T: Low inetastatic potential of done from murine colon adenocarcinoma 26 increased by transfection of activated c-erbB-2 gene. J. Natl. Cancer Inst. 1990; 82: 1633-1636.
19. Tsujino T, Yoshida K, Nakayama H, Iio H, Shimosato T, Tahara E: Alterations of oncogenes in inetastatic tumors of human gastric carcinomas. Br. J. Cancer 1990; 62: 226-230.
20. Maehara Y, Moriguchi S, Kakeji Y, Kohnoe S, Korenaga D, Haragachi M, Sugimachi K.: Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery 1991); 110: 820-823.
21. Maekawa S, Saku M, Maeham Y, Sadanaga N, Ikejiri K, Anai H, Kuwano H, Sugimachi K: Surgical treatment for advanced gasstric cancer. Hepato-Gastroenterol. 1996; 43: 182-190.
22. Yonemura Y, Tsugawa: K, Fushida S, Matsumoto H, Ninomiya I, Sugiyama K, Fujimura T, Nishimura G, Miwa A, Miyazaki I: Lymph node metastasis and surgical management of gastric cancer invading the esophagus. Hepato-Gastroenterol. 1995; 42: 37-42.
23. Maehara Y, Okuyama T, Moriguchi S, Orita H, Kusumoto H, Korenaga D, Sugimachi K: Prophylactic lymph node dissection in patients with advanced gastric cancer promotes increasd survival time. Cancer 1992; 70: 392-395.